ELAHERE Drug Profile
Summary for Tradename: ELAHERE
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 1 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for ELAHERE Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for ELAHERE Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for ELAHERE Derived from Patent Text Search
No patents found based on company disclosures
ELAHERE Market Dynamics and Financial Trajectory: Sales Growth, Patent Protection, Competition, and Generic Risk
ELAHERE (mirvetuximab soravtansine-gynx) is AbbVie’s antibody-drug conjugate for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The drug moved from accelerated approval in 2022 to regular FDA approval in March 2024 after positive MIRASOL results. Its commercial outlook depends on expanding treatment use, improving physician adoption, sustaining reimbursement, and extending the FRα-targeted market beyond heavily pretreated ovarian cancer.
ImmunoGen generated $105.2 million in ELAHERE net product revenue in 2023 before its acquisition by AbbVie. AbbVie acquired ImmunoGen for approximately $10.1 billion, making ELAHERE the central commercial asset in the transaction. The drug has potential to become a billion-dollar product, but its near-term market remains concentrated in a relatively small, heavily pretreated ovarian-cancer population.
What is ELAHERE and how does it work?
ELAHERE combines a monoclonal antibody directed at FRα with the maytansinoid payload DM4. The antibody binds FRα on tumor cells, the conjugate is internalized, and DM4 disrupts microtubules after intracellular release.
| Attribute | ELAHERE |
|---|---|
| Active ingredient | Mirvetuximab soravtansine-gynx |
| Drug class | FRα-directed antibody-drug conjugate |
| Manufacturer | AbbVie |
| Original developer | ImmunoGen |
| FDA approval pathway | Biologics license application |
| Initial FDA approval | Accelerated approval, November 14, 2022 |
| Regular approval | March 22, 2024 |
| Initial indication | FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer |
| Required biomarker | High FRα expression under the original accelerated-approval indication |
| Companion diagnostic | Ventana FOLR1 RxDx assay |
| Administration | Intravenous infusion |
| Main safety issue | Ocular toxicity, including keratopathy and visual impairment |
| Commercial owner | AbbVie |
The FDA’s March 2024 regular approval was based on the confirmatory MIRASOL trial, which showed superior progression-free survival and overall survival compared with investigator’s-choice chemotherapy in patients with FRα-positive platinum-resistant ovarian cancer.[1]
What is the FDA regulatory status of ELAHERE?
ELAHERE has regular FDA approval, not merely accelerated approval. That distinction reduces regulatory risk because the confirmatory trial obligation supporting the original approval was fulfilled.
FDA approval timeline
| Date | Regulatory event |
|---|---|
| November 14, 2022 | FDA grants accelerated approval for adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic therapies |
| 2023 | Commercial launch and physician adoption begin |
| March 22, 2024 | FDA converts ELAHERE to regular approval based on MIRASOL |
| 2024 onward | AbbVie assumes commercial development and global expansion responsibilities after completing the ImmunoGen acquisition |
The regular approval strengthens payer confidence and limits the risk of withdrawal based on an unsuccessful confirmatory study. It also improves the asset’s strategic value in licensing, partnering, and acquisition analyses.
The principal regulatory limitation is the drug’s safety profile. ELAHERE carries a boxed warning for ocular toxicity. Patients require baseline and periodic ophthalmic examinations, prophylactic eye drops, and dose modification or interruption when clinically indicated.[2] These requirements increase treatment-management complexity and can restrict use in community oncology settings without established ophthalmology coordination.
How large is the ELAHERE market?
ELAHERE addresses a biomarker-selected segment of ovarian cancer. The initial market is narrower than the total ovarian-cancer population because treatment requires platinum resistance, prior systemic therapy, and high FRα expression.
The market has four main expansion levers:
- Increased testing for FRα expression.
- Earlier use in the platinum-resistant treatment sequence.
- Treatment of patients after fewer prior lines.
- Expansion into additional FRα-positive solid tumors.
The commercial opportunity is constrained by the declining population of patients with platinum-resistant disease after multiple prior therapies, competing chemotherapy regimens, toxicity management, and the need for diagnostic confirmation.
Market-positioning factors
| Factor | Commercial effect |
|---|---|
| High FRα biomarker requirement | Concentrates benefit in a responsive population but limits eligible patients |
| MIRASOL survival data | Supports use over physician’s-choice chemotherapy |
| ADC mechanism | Differentiates ELAHERE from non-targeted chemotherapy |
| Ocular toxicity | Creates monitoring burden and can limit persistence |
| Regular FDA approval | Improves reimbursement and treatment guideline positioning |
| Single approved indication | Leaves substantial dependence on ovarian-cancer expansion |
| AbbVie ownership | Provides larger commercial infrastructure and global launch capacity |
The most important near-term commercial question is whether ELAHERE becomes a preferred option in platinum-resistant ovarian cancer or remains a later-line specialty therapy.
How much revenue has ELAHERE generated?
ImmunoGen reported $105.2 million in ELAHERE net product revenue for 2023. The product was launched in late 2022, so 2023 was its first full commercial year. Revenue increased during the year as oncologists gained experience, FRα testing expanded, and the drug entered treatment pathways.
| Period | ELAHERE net product revenue | Owner |
|---|---|---|
| 2022 | Commercial launch year; partial revenue | ImmunoGen |
| 2023 | $105.2 million | ImmunoGen |
| 2024 | AbbVie commercial period after acquisition; reported revenue should be evaluated using AbbVie segment disclosures | AbbVie |
| Long-term target | Potential multibillion-dollar strategic asset, subject to indication and geographic expansion | AbbVie |
ImmunoGen’s 2023 total revenue was approximately $333.8 million, with ELAHERE representing the company’s principal product revenue stream.[3] The product therefore had high concentration risk before the acquisition. AbbVie’s acquisition price reflected the expected future value of ELAHERE rather than the drug’s 2023 sales alone.
What does the AbbVie acquisition imply for ELAHERE’s financial trajectory?
AbbVie agreed to acquire ImmunoGen for approximately $10.1 billion, including assumed debt, in a transaction announced in November 2023 and completed in February 2024.[4] The acquisition gave AbbVie:
- A commercial-stage oncology ADC.
- A validated FRα biomarker strategy.
- A product with positive overall-survival data.
- A platform and intellectual-property position in ADC development.
- A potential growth asset to offset pressure on mature products.
AbbVie’s financial return depends on sales growth exceeding the cost of the acquisition, development spending, manufacturing investment, commercial infrastructure, and any market-access discounts. A $1 billion annual sales product would represent a substantial increase over ImmunoGen’s 2023 revenue base, but that outcome requires broader use than the original late-line indication.
What patents protect ELAHERE?
ELAHERE is protected by a combination of biologic, antibody, conjugate, linker, payload, formulation, manufacturing, and method-of-use intellectual property. The relevant estate is more complex than a conventional small-molecule patent portfolio.
Core protection categories
| Protection category | Relevance to ELAHERE |
|---|---|
| Anti-FRα antibody patents | Protect antibody sequences, binding sites, and related variants |
| ADC composition patents | Protect the antibody-drug conjugate and antibody-payload combinations |
| Linker patents | Protect chemical linkage between the antibody and DM4 payload |
| Payload patents | Protect maytansinoid derivatives and cytotoxic compounds |
| Conjugation patents | Protect drug-antibody attachment methods and drug-loading characteristics |
| Manufacturing patents | Protect production, purification, conjugation, and quality-control processes |
| Method-of-use patents | Protect treatment of FRα-positive cancers and defined patient populations |
| Diagnostic-related rights | Support patient selection through FRα testing |
ELAHERE is a biologic licensed under the Public Health Service Act. Its exclusivity profile therefore includes regulatory biologic reference-product exclusivity, patent protection, and potential protection for manufacturing and clinical-use methods.
When does ELAHERE lose regulatory exclusivity?
ELAHERE received its first FDA licensure in 2022. Under the Biologics Price Competition and Innovation Act, a biosimilar generally cannot be approved until 12 years after the reference product’s first licensure, subject to statutory treatment of the specific product and application.[5] On that basis, the core U.S. regulatory exclusivity period would extend into approximately November 2034.
Regulatory exclusivity does not eliminate earlier biosimilar filing activity. A biosimilar sponsor may begin development and submit an application before the 12-year approval bar expires. Patent litigation, settlement agreements, and patent-term analysis could determine the actual commercial launch date.
A precise commercial exclusivity date cannot be reduced to the 12-year period alone. Patent terms may extend beyond regulatory exclusivity, while some patent claims may expire earlier or be vulnerable to invalidity or noninfringement challenges.
Does ELAHERE have Orange Book patents?
No conventional Orange Book analysis applies to ELAHERE in the same way it applies to small-molecule drugs. ELAHERE is a biologic, so its reference-product and biosimilar information is handled through the FDA’s Purple Book framework rather than an abbreviated new drug application and Orange Book listing.
What does this mean for generic entry?
There is no standard ANDA pathway for a generic version of ELAHERE. The relevant competitor would be a biosimilar or interchangeable biosimilar submitted under section 351(k) of the Public Health Service Act.
This creates several differences:
- No conventional Paragraph IV certification against Orange Book patents.
- No Hatch-Waxman 30-month stay based on an ANDA Paragraph IV filing.
- Biosimilar applicants must establish high similarity and lack of clinically meaningful differences.
- The reference product’s antibody, conjugation profile, payload distribution, and manufacturing controls create technical barriers.
- Patent disputes may proceed under the BPCIA framework or conventional patent litigation theories.
Are there Paragraph IV challenges to ELAHERE?
A conventional Paragraph IV challenge is not the expected route for ELAHERE because the drug is a biologic rather than an Orange Book-listed small molecule. Publicly reported generic Paragraph IV litigation is therefore not the primary early-warning indicator for ELAHERE competition.
Potential future biosimilar disputes could involve:
- Patent-listing and patent-disclosure procedures under the BPCIA.
- Antibody sequence and binding claims.
- ADC composition claims.
- Linker-payload claims.
- Conjugation and manufacturing claims.
- Treatment-method claims.
- Patent-term and obviousness challenges.
The absence of an ANDA Paragraph IV filing does not mean the estate is immune from challenge. It means the competitive pathway differs from the generic-drug model.
How strong is the ELAHERE patent estate?
The estate is strategically strong because ELAHERE combines biologic exclusivity with technically demanding ADC manufacturing. The strongest barriers are likely to be product-characterization and manufacturing complexity rather than a single method-of-use patent.
Strengths
- The drug is a targeted ADC with multiple potential claim layers.
- Manufacturing consistency is difficult to reproduce for complex conjugates.
- FRα-positive patient selection supports defined method-of-use claims.
- The MIRASOL data provide clinical support for treatment-specific claims.
- AbbVie has greater resources for global patent prosecution and litigation.
- Regulatory exclusivity extends into the 2030s.
Weaknesses
- ADC platforms attract competing technologies.
- Antibody and payload substitution may allow design-around strategies.
- Method-of-use claims may be narrower than composition claims.
- Ocular toxicity may limit broader adoption.
- Competing FRα ADCs could reduce the commercial value of the target.
- Patent validity challenges may focus on obviousness, written description, enablement, and claim scope.
The commercial estate is stronger than a single-patent product profile but should be assessed patent family by patent family. The key question is whether enforceable composition and manufacturing claims survive until or beyond the end of regulatory exclusivity.
Which companies are challenging ELAHERE’s market position?
ELAHERE competes with established ovarian-cancer treatments and emerging FRα-directed therapies.
Current and adjacent competitors
| Competitor | Company | Competitive position |
|---|---|---|
| Physician’s-choice chemotherapy | Multiple manufacturers | Comparator in MIRASOL and a direct treatment alternative |
| Avastin (bevacizumab) | Roche | Established ovarian-cancer biologic used in selected treatment settings |
| Trodelvy (sacituzumab govitecan) | Gilead Sciences | ADC competitor with broader oncology visibility, although not an identical FRα-targeted product |
| Zejula (niraparib) | GSK | Maintenance-oriented ovarian-cancer therapy with a different treatment position |
| Rubraca (rucaparib) | Pharma& | PARP-inhibitor class competitor with a different biomarker and treatment context |
| FRα-directed ADC programs | Multiple biotechnology companies | Potential direct competition if approved |
Potential direct FRα competitors include antibody-drug conjugate programs such as luveltamab tazevibulin, also known as STRO-002, and other FRα-targeted agents in development. Their competitive effect depends on trial results, label breadth, safety, dosing, and commercial timing.
ELAHERE’s first-mover advantage is meaningful, but it will weaken if another FRα-directed therapy demonstrates superior survival, lower ocular toxicity, easier administration, or use in earlier treatment lines.
What is the litigation and settlement status of ELAHERE?
No major publicly established patent settlement has defined ELAHERE’s generic or biosimilar launch timeline. The most important legal risks are prospective:
- Biosimilar patent challenges after the reference product’s commercial value becomes clear.
- Patent disputes involving antibody sequence or FRα binding.
- Challenges to ADC linker, payload, and conjugation claims.
- Litigation involving manufacturing processes.
- Patent-term disputes affecting biosimilar launch timing.
- Method-of-use disputes involving label carve-outs or induced infringement.
Because ELAHERE is a biologic, litigation monitoring should focus on BPCIA notices, patent-family prosecution, district-court complaints, inter partes review activity, and biosimilar development disclosures rather than only Orange Book updates.
What manufacturing barriers protect ELAHERE?
Manufacturing is a material barrier to competition. ELAHERE requires production of the antibody, chemical conjugation to a maytansinoid derivative, purification, characterization, sterility control, and release testing.
Important technical variables include:
- Drug-to-antibody ratio.
- Payload distribution.
- Linker stability.
- Aggregation profile.
- Free-payload levels.
- Potency and binding activity.
- Batch-to-batch consistency.
- Impurity removal.
- Stability during storage and administration.
A biosimilar sponsor does not need to duplicate every manufacturing step, but it must demonstrate a highly similar product without clinically meaningful differences. For ADCs, analytical comparability can be more difficult than for simpler monoclonal antibodies.
Manufacturing capacity may also influence supply economics. AbbVie can use larger-scale biologics infrastructure than ImmunoGen, potentially reducing unit costs and supporting international expansion. The company must still manage cold-chain logistics, specialized ADC facilities, and quality-control requirements.
How does ELAHERE compare with other ovarian-cancer drugs?
| Dimension | ELAHERE | Conventional chemotherapy | Bevacizumab | PARP inhibitors |
|---|---|---|---|---|
| Target | FRα | Broad cytotoxic mechanism | VEGF pathway | DNA-repair vulnerability |
| Biomarker | FRα expression | Usually none | Usually none | BRCA or homologous-recombination context in selected uses |
| Treatment setting | Platinum-resistant disease after prior therapy | Multiple lines | Multiple ovarian-cancer settings | Primarily maintenance or selected treatment settings |
| Administration | Intravenous infusion | Varies | Intravenous infusion | Oral |
| Differentiation | Targeted ADC with survival data | Lower specificity | Established biologic | Oral targeted maintenance |
| Main limitation | Ocular toxicity and biomarker testing | Systemic toxicity | Hypertension, bleeding, vascular risks | Hematologic and other class-specific toxicities |
ELAHERE’s value proposition is strongest when physicians prioritize targeted treatment and MIRASOL-supported survival outcomes over the convenience of oral therapy or the familiarity of chemotherapy.
What generic or biosimilar launch risks exist?
The earliest realistic biosimilar competition is constrained by the 12-year reference-product exclusivity period, which points to the mid-2030s based on the 2022 first licensure. Patent protection could push effective market entry later, while an unsuccessful patent challenge could reduce the delay.
Launch scenarios
| Scenario | Commercial timing | Market effect |
|---|---|---|
| Strong patent estate and limited biosimilar activity | After regulatory exclusivity and later patent expiry | AbbVie retains high pricing power |
| One biosimilar enters after negotiated settlement | Potentially before full patent expiry | Moderate price erosion and payer pressure |
| Multiple biosimilars enter after litigation | Later 2030s or beyond | Greater discounts and reduced treatment economics |
| Direct FRα competitor launches first | Before biosimilar entry | Share loss without direct price erosion |
| Label expansion succeeds | Before competitive entry | Larger revenue base and stronger franchise value |
The most immediate threat is not generic substitution. It is therapeutic competition from other ADCs and treatment regimens that reduce ELAHERE’s share of the FRα-positive population.
What licensing deals affect ELAHERE?
The central transaction is AbbVie’s acquisition of ImmunoGen. The deal transferred ownership of ELAHERE, ImmunoGen’s ADC technology, and related intellectual property to AbbVie. The transaction closed in February 2024 for approximately $10.1 billion.[4]
The acquisition changed ELAHERE’s business model in three ways:
- ImmunoGen moved from a single-product biotechnology company to an AbbVie oncology asset.
- AbbVie gained control of worldwide commercial strategy and lifecycle management.
- ELAHERE obtained access to AbbVie’s regulatory, market-access, manufacturing, and international infrastructure.
The deal also raises the return threshold. AbbVie must generate sufficient cumulative sales and lifecycle value to justify the acquisition premium, not merely maintain ImmunoGen’s pre-acquisition growth rate.
What is the revenue exposure and investment outlook for ELAHERE?
ELAHERE was effectively ImmunoGen’s revenue engine, but it is one component of AbbVie’s diversified pharmaceutical portfolio. That lowers corporate concentration risk for AbbVie while increasing the importance of ELAHERE’s standalone performance inside the oncology business.
The principal financial drivers are:
- FRα testing penetration.
- Treatment-line expansion.
- Duration of therapy.
- Net price after payer discounts.
- International launch timing.
- Ocular-toxicity management.
- Manufacturing cost per dose.
- Competition from other ADCs.
- Success in additional tumor types.
Bull-case trajectory
A favorable outcome would include strong uptake in platinum-resistant ovarian cancer, use after fewer prior therapies, rapid international rollout, and positive data in additional FRα-positive cancers. This could support annual sales above the early commercial base and potentially into blockbuster territory.
Base-case trajectory
The more conservative case is sustained growth within a narrow ovarian-cancer indication, with revenue reaching several hundred million dollars annually but facing competition and toxicity-related treatment discontinuation.
Downside trajectory
The main downside risks are weak biomarker testing, limited duration of treatment, ocular toxicity, disappointing expansion trials, superior competing ADCs, and payer restrictions. These factors could limit ELAHERE to a specialty product despite the MIRASOL approval.
Key Takeaways
- ELAHERE is a regular FDA-approved FRα-directed ADC owned by AbbVie.
- ImmunoGen reported $105.2 million in ELAHERE net product revenue for 2023.
- AbbVie’s approximately $10.1 billion acquisition of ImmunoGen reflects expectations for substantial future growth.
- The drug’s core regulatory exclusivity extends into approximately 2034 based on its 2022 first licensure.
- Orange Book and Paragraph IV analysis is not the correct framework because ELAHERE is a biologic.
- Future competition is more likely to emerge from biosimilars and competing ADCs than from conventional generics.
- Ocular toxicity, biomarker testing, and limited initial disease scope are the principal commercial constraints.
- Manufacturing complexity strengthens the practical barrier to biosimilar competition.
- The largest value-creation opportunity is expansion into earlier treatment lines and additional FRα-positive cancers.
- The largest strategic risk is loss of share to a safer or more effective FRα-directed ADC.
FAQs About ELAHERE Market and Patent Outlook
When did ELAHERE receive full FDA approval?
The FDA granted regular approval on March 22, 2024, after MIRASOL confirmed progression-free and overall-survival benefits versus physician’s-choice chemotherapy.
Is ELAHERE a small-molecule drug or a biologic?
ELAHERE is a biologic antibody-drug conjugate licensed through a biologics license application. Biosimilar competition would proceed under the 351(k) pathway.
Can a generic version of ELAHERE be filed through an ANDA?
No. A conventional ANDA and Paragraph IV certification apply to small-molecule drugs listed in the Orange Book, not to ELAHERE as a biologic reference product.
What is the most important safety issue affecting ELAHERE sales?
Ocular toxicity is the principal commercial and clinical limitation. Patients require ophthalmic monitoring and preventive eye-care measures.
Could ELAHERE become a blockbuster drug?
Yes, but reaching blockbuster sales requires growth beyond the initial late-line ovarian-cancer population through earlier-line use, international expansion, or additional FRα-positive indications.
References
-
U.S. Food and Drug Administration. (2024, March 22). FDA grants regular approval to mirvetuximab soravtansine-gynx for ovarian cancer. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024). ELAHERE prescribing information. AbbVie Inc. https://www.accessdata.fda.gov/
-
ImmunoGen, Inc. (2024). 2023 annual report, Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov/
-
AbbVie Inc. (2024, February 12). AbbVie completes acquisition of ImmunoGen. https://news.abbvie.com/
-
U.S. Food and Drug Administration. (2023). Biologics Price Competition and Innovation Act of 2009. https://www.fda.gov/աբեր
More… ↓
